At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,334 enrolled
Drug / intervention
Astegolimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 2 clinical trial evaluating Astegolimab and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 1,334 participants across 181 sites in 24 countries.
Detailed Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesArgentina, Australia, Belgium, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Hong Kong, Israel, Mexico, Netherlands, New Zealand, Peru, Poland, Romania, South Africa, South Korea, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartOct 2021
Primary CompletionFeb 2025
Study CompletionJul 2025
TodayJul 2026
First PostedSep 8, 2021
Enrollment StartOct 5, 2021
Primary CompletionFeb 24, 2025
Study CompletionJul 7, 2025
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 4.8 years ago
Interventions
Astegolimabdrug
Participants will receive SC astegolimab Q2W or Q4W.
Placebodrug
Participants will receive SC placebo Q2W.